Xueting Luo

Title: Innovator Xueting Luo: Pioneering Gene Therapy for Retinitis Pigmentosa

Introduction: Xueting Luo is an accomplished inventor based in Shanghai, China, known for his innovative work in gene therapy. With a focus on treating retinitis pigmentosa, he has contributed significantly to medical research and biotechnology through his patents.

Latest Patents: Xueting Luo holds a patent for a gene therapy vector designed for treating retinitis pigmentosa. This invention includes a target-specific optimization design performed on the PROM1 gene coding sequence, resulting in a nucleotide sequence that enhances the efficient expression of the PROM1 protein in mammalian cells. The patented technology involves constructing a recombinant AAV virus capable of expressing the normal human PROM1 protein. The optimized PROM1 coding sequence has demonstrated an expression level that is more than three times higher than the non-optimized version, showcasing its suitability for mammalian cell expression.

Career Highlights: Working at Shanghai Innostellar Biotherapeutics Co., Ltd., Xueting Luo has been at the forefront of gene therapy research. His dedication to improving therapeutic strategies for genetic disorders highlights his role as a significant contributor to the field of biomedicine.

Collaborations: Xueting collaborates closely with his colleague Xiaodong Sun, who plays a vital role in advancing their research initiatives. Their partnership is essential for tackling complex challenges in the development of gene therapies.

Conclusion: Xueting Luo's innovative approach to gene therapy for retinitis pigmentosa positions him as a key inventor in the field. His work not only holds promise for patients suffering from genetic disorders but also sets a precedent for future advancements in biotechnology.